Cargando…
2140. Biological Features of Response to VE303, a Defined Bacterial Consortium, in Patients with Clostridioides difficile Infection (CDI): Results from the Phase 2 CONSORTIUM Study
BACKGROUND: Fecal transplant and other donor-derived treatments promote a gut environment resistant to CDI, but these treatments have inherently variable quality attributes, are difficult to scale, and can transfer harmful pathogens. VE303 is a rationally defined consortium of 8 purified, clonal str...
Autores principales: | Menon, Rajita, Crossette, Emily, Bhattarai, Shakti, Bucci, Vanni, Prince, Amanda L, Faith, Jeremiah, Olle, Bernat, Silber, Jeffrey L, Norman, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678313/ http://dx.doi.org/10.1093/ofid/ofad500.1763 |
Ejemplares similares
-
1953. VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota After Vancomycin (vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
por: Bobilev, Dmitri, et al.
Publicado: (2019) -
Consortium of Probiotics Attenuates Colonization of Clostridioides difficile
por: Li, Xianping, et al.
Publicado: (2019) -
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021) -
Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022) -
684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)